RxDoctor Payments Data

David Rosenheck, MD

Gastroenterology · Edison, NJNPI 1811995046

Payments from drug & device makers

$10,939in general payments, 2019–2025

Across 785 payments — averaging $13.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$557
  • Pfizer$515
  • Lilly USA, LLC$419
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$10,914100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,939 in reported general payments places this provider in the 85th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$276,393
Medicare patients
901
Services billed
2,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$324,864
Humira PenAdalimumab14$112,811
RinvoqUpadacitinib13$97,525
Humira(Cf) PenAdalimumab14$94,296
SimponiGolimumab12$86,037
XifaxanRifaximin23$74,427
Cimzia (2 Pack)Certolizumab Pegol13$73,186
LinzessLinaclotide69$65,455
CreonLipase/Protease/Amylase20$64,675
ZenpepLipase/Protease/Amylase16$51,692
Dexlansoprazole DrDexlansoprazole142$45,360
Mesalamine17$18,986
VoqueznaVonoprazan Fumarate23$17,567
Pantoprazole Sodium543$8,816
DexilantDexlansoprazole14$6,737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara, Simponi$1,331$410,90124 claims
AbbVieRinvoq, Linzess, Creon$2,762$227,655102 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,711$74,42723 claims
UCB, Inc.Cimzia (2 Pack)$108$73,18613 claims
Aimmune Therapeutics, Inc.Zenpep$252$51,69216 claims
Phathom Pharmaceuticals, Inc.Voquezna$316$17,56723 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$557$6,73714 claims
Braintree Laboratories, Inc.Sutab$36$3,06419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →